Estonia HyQvia (Human Normal Immunoglobulin (10%) and Recombinant Human Hyaluronidase) CIDP Launch 2024

Agenda

14.00–15.00

Registration and coffee

 

 

15.00–15.10

Welcome – Katrin Gross-Paju, MD PhD (Estonia)

15.10–15.20

Takeda commitment in Plasma-Derived Therapies (PDT)

15.20–15.40

Multidisciplinary team in rare immune-mediated peripheral neuropathies – Katrin Gross-Paju, MD PhD (Estonia)

15.40–16.00

Neuromuscular ultrasound (NMUS) as valuable addition to diagnostics – Assoc. Prof Liis Väli, MD PhD (Estonia)

16.00–16.20

CIDP treatment – Laura Tibar, MD (Estonia)

16.20–16.40

How to assess CIDP disease severity and progression? – Evelina Grušauskienė, MD (Lithuania)

 

 

16.40–17.00

Coffee break

 

 

17.00–17.20

CIDP treatment personalization – when treatment moves home – Lars Kjøbsted Markvardsen, MD PhD (Denmark)

17.20–17.40

Practical experience with fSCIG in CIDP maintenance - dosing regimen (ramp-up), large volumes infused at once, improvement in quality of life  – Lars Kjøbsted Markvardsen, MD PhD (Denmark)

17.40–18.00

Patient case from Latvia – Assoc. Prof Viktorija Kenina, MD PhD (Latvia)

18.00–18.30

Panel Discussion, all

18.30–18.35

Closing Remarks – Katrin Gross-Paju, MD PhD (Estonia)

 

 

18.45–20.15

Dinner

 

CIDP, Chronic Inflammatory Demyelinating Polyneuropathy; fSCIG, facilitated subcutaneous immunoglobulin.

 

Participating in the conference is free. To register, please fill in the online registration form down below. You should also fill in additional information to finish the registration (please include your personal e-mail address in there). 

Registration is open until the 7th of November.

For questions, please contact us: konverentsid@celsius.ee.

 

 

For detailed information about an individual medicinal product, please read last approved Summary of Product Characteristics.

Please read all of the Summary of Product Characteristics before prescribing HyQvia (human normal immunoglobulin 10% and recombinant human hyaluronidase) EU SmPC, May 2024 https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf.

Hospital product.

Therapeutic indications:

Replacement therapy in adults, children, and adolescents (0 to 18 years) in:

Primary immunodeficiency syndromes (PID) with impaired antibody production

 

Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections,

ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum

IgG level of < 4 g/L.

*PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide

and polypeptide antigen vaccines.

Immunomodulatory therapy in adults, children, and adolescents (0 to 18 years) in:

Chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after

stabilization with IVIg.

 

Marketing Authorisation Holder: Baxalta Innovations GmbH, Industriestrasse 67, A-1221 Vienna, Austria.

In case of any questions please contact Takeda Pharma OÜ, Järve 2, 11314 Tallinn, https://www.takeda.com/et-ee, e-mail ee.info@takeda.com, tel 617 7669

Job number: C-APROM/EE/HYQ/0034 DOP: October 2024

 

Meeting is initiated, organized and funded by Takeda. Only for HealthCare Professionals. Please note that all medicinal products mentioned may not be authorized/available in all countries.

Copyright 2024 Takeda Pharmaceutical Company Limited. All rights reserved